Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102451 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13102510 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13102431 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13102436 | 0.89 | TSHR (0.49) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13101634 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13101615 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPK1KDM4ETSHRLMNA | |
| SCHEMBL13102239 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPK1KDM4ETSHRLMNA | |
| SCHEMBL13101626 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPK1KDM4ETSHRLMNA | |
| SCHEMBL13101624 | 0.85 | CCNA2 (0.45) | SMN1; SMN2MAPK1KDM4ETSHRCCNA2 | |
| SCHEMBL13101710 | 0.84 | ALDH1A1 (0.41) | LMNACSNK1DALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7223768-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885MAPK1 1243/4885KDM4E 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.